Overview: Hepatitis B Surface Antigen (HBsAg) + Antibody (HBsAb) Rapid TestIntroduction: The Hepatitis B Surface Antigen (HBsAg) + Antibody (HBsAb) Rapid Test is a diagnostic tool designed to detect HBsAg and HBsAb in serum, whole blood, or saliva samples, facilitating the screening of hepatitis B infection or immunity. Caused by the hepatitis B virus transmitted via blood or bodily fluids, this viral infection presents with jaundice, fatigue, and severe complications like cirrhosis if untreated, particularly in unvaccinated populations. Per the 2023 World Health Organization guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in high-risk settings. This rapid diagnostic falls under virology and targets individuals with liver symptoms or exposure risks, addressing the challenge of early detection to guide antiviral therapy or vaccination. With morbidity rates elevated due to chronic carriers, the test supports public health efforts by enabling early identification, facilitating management, and reducing transmission. Its multi-sample capability enhances its utility.Other Names: HBsAg/HBsAb Combo Rapid Test.FDA Status: FDA approved, CLIA certified for virology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Abbott, this test advanced HBV detection, providing a rapid alternative to ELISA with antigen and antibody detection.Purpose: The test screens for HBsAg and HBsAb to guide infection or immunity diagnosis, assess liver involvement, and inform treatment and prevention strategies.Test Parameters: Presence of HBsAg and HBsAb, detected with reasonable specificity to indicate active infection or immunity, typically detectable in serum or blood within 1-6 months of exposure.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report jaundice, fatigue, or recent blood exposure.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile SST or EDTA tubes/containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen and antibody integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade antigens and antibodies, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on jaundice, fatigue, liver disease, or prior HBV exposure, as well as any vaccination history or recent blood transfusion.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including cirrhosis, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or early sampling before seroconversion can affect results. Correlation with HBV DNA or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive HBsAg result indicates possible active HBV, while a positive HBsAb suggests immunity, necessitating further investigation like HBV DNA or hepatology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled too early.Specialist Consultation: Infectious disease specialists or hepatologists should be consulted for case management, treatment planning, and coordination with public health authorities.Additional Supporting Tests: HBV DNA, HBeAg, or liver function tests for confirmation.Test Limitations: The test may produce false negatives in early infection or false positives due to cross-reactivity, requiring a comprehensive diagnostic approach that includes molecular methods.References: WHO Guidelines 2023, Journal of Hepatology 2024, Virology 2025.